Context Therapeutics (CNTX) Other Non-Current Assets (2020 - 2023)
Context Therapeutics (CNTX) posted Other Non-Current Assets of $24000.0 for Q2 2023, down 8.35% sequentially from $26188.0 in Q1 2023, and down 64.58% YoY from $67750.0 in Q2 2022.
Context Therapeutics (CNTX) Other Non-Current Assets (2020 - 2023) Analysis & Trends
Context Therapeutics has reported Other Non-Current Assets for 4 years, with the latest figure at $24000.0 in Q2 2023.
- Quarterly Other Non-Current Assets fell 64.58% year-over-year to $24000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $24000.0 (down 64.58% YoY) and the FY2022 annual result came in at $32750.0, down 34.5% from the prior year.
- Other Non-Current Assets eased to $24000.0 in Q2 2023 per CNTX's latest filing, from $26188.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $67750.0 in Q2 2022 and troughed at $24000.0 in Q2 2023.
- A 4-year average of $41481.1 and a median of $39313.0 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2021 and 2023: Other Non-Current Assets dropped 0.73% in 2021, then slumped 64.58% in 2023.
- Over 4 years, Other Non-Current Assets stood at $50367.0 in 2020, then retreated by 0.73% to $50000.0 in 2021, then sank by 34.5% to $32750.0 in 2022, then retreated by 26.72% to $24000.0 in 2023.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $24000.0, $26188.0, and $32750.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 26,188.00 |
| Dec 31, 2022 | 32,750.00 |
| Sep 30, 2022 | 39,313.00 |
| Jun 30, 2022 | 67,750.00 |
| Dec 31, 2021 | 50,000.00 |
| Dec 31, 2020 | 50,367.00 |